Chemo Triplet May Boost Survival in Rare Soft-Tissue Sarcoma
Adding temozolomide to a combination of vincristine and irinotecan (VIT) improved tumor response and survival in patients with relapsed or refractory rhabdomyosarcoma in a European phase II trial. In the trial of over 100 patients, the group who received temozolomide had a numerically improved objective response rate (ORR) after two cycles of treatment versus the […]